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ABSTRACT
Introduction: Treat-and-extend (T&E) and pro
re nata (PRN; ‘as needed’) regimens of intravit-
real anti-vascular endothelial growth factor
(VEGF) treatment have been found to reduce
the injection burden on patients and improve
the cost effectiveness of the treatment of mac-
ular edema. The aim of this study was to assess
the effectiveness of a T&E regimen of afliber-
cept, in a clinical setting, in patients with dia-
betic macular edema (DME) who were either
intravitreal anti-VEGF therapy naive or with
minimal exposure to anti-VEGF (B 6 treat-
ments) in the previous 12 months.
Methods: This prospective, single arm, open label
study recruited patients with DME (macular
thickness of C 300 lm) and best-corrected visual
acuity (BCVA) between 28-78 ETDRS letters. Par-
ticipants received five loading doses of intravitreal
aflibercept at 4-weekly intervals. BCVA measure-
ments andmacular optical coherence tomography
were performed at each visit. If no disease activity
wasdetected, treatment intervalswere increasedby
2 weeks to a maximum of 12 weeks. Outcome
measures included: changes in BCVA and retinal
anatomical measures (central foveal thickness
[CFT] and centralmacular volumewithin 6 mmof
the fovea [CSVol]) between baseline and 2 years,
patient treatment intervals; and adverse events.
Results: Of the 36 patients who provided
informed consent to participate in the study
and were screened, 26 patients (eyes) were eli-
gible to participate in the study. After regression
analysis, adjustment for repeated measures, and
significant covariates, the mean BCVA increased
by 3.8 letters (95% confidence interval [CI] 1.1,
6.4) and the CFT and CSVol decreased by
127.2 lm (95% CI 91.7, 162.5) and 1.6 mm3
(95% CI 1.2, 2.0), respectively, over the course
of the study. In the second year, 16 of the 25
patients still participating had their treatment
intervals extended to 12 weeks. There was no
evidence of any new adverse events that would
require changes to the aflibercept safety profile.
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Key Summary Points
Why do this study?
Regular intravitreal injections of anti-
vascular endothelial growth factor (VEGF)
are currently the first-line treatment for
centrally located diabetic macular edema
(DME).
In clinical trials, treat and extend (T&E)
and pro re nata (PRN; ‘as needed’)
regimens of intravitreal anti-VEGF
treatment have been found to reduce the
injection burden on patients and improve
the cost effectiveness of the treatment of
macular edema.
The aim of this study was to assess the
effectiveness of a T&E regimen of
aflibercept, in a clinical setting, in patients
presenting DME either intravitreal anti-
VEGF therapy naive or with relapsed DME
with minimal exposure (B 6 treatments)
to anti-VEGF in the previous 12 months.
What did we learn?
At the end of 2 years, 75% of the
participants remaining in the study had
their treatment intervals extended to the
maximum 12 weeks with no signs of
disease activity, indicating that a T&E
regimen of aflibercept is a practical
alternative to PRN treatment with regular
review.
INTRODUCTION
Diabetes accounts for a significant burden of glo-
bal chronic disease [1], with the ophthalmic
complications of diabetic retinopathy (DR) and
diabetic macular edema (DME) representing the
commonest causes of early onset blindness
worldwide [2]. More than 1.7 million (7%) Aus-
tralians live with diabetes. The prevalence of the
disease increases with age and is estimated to be
threefold higher in aboriginal Australians than in
CaucasianAustralians [3]. In the2015–16National
Eye Health Survey (NEHS) of Australian adults ([
40 years of age), 29% of those who self-reported
diabetes also had DR; 8% had vision-threatening
DR and 4% had clinically significant DME [4].
In the mid-1980s laser macular photocoagu-
lation was recommended as the gold standard
treatment for DME [5]. However, detection of
high levels of vascular endothelial growth factor
(VEGF) in eyes with macular edema secondary
to microvascular disease (notably age-related
macular degeneration, retinal vein occlusion
and DME) [6] and a greater understanding of its
role in the pathogenesis of these conditions
resulted in the development of pharmaceutical
agents targeting VEGF receptors [7, 8]. Further-
more, consistent evidence from clinical trials
and clinical practice demonstrating the superi-
ority of anti-VEGF treatment over laser treat-
ment, particularly in cases where the efficacy
outcome of interest was visual acuity rather
than anatomical response [9–13], has resulted in
the adoption of anti-VEGFs as first-line therapy
for the treatment of macular edema.
In Australia, aflibercept (Eylea; Regeneron,
Tarrytown, NY, USA) and ranibizumab (Lucen-
tis; Genentech, Inc., San Francisco, CA, USA)
are the only anti-VEGF agents indicated for the
treatment of DME. Both have been listed for re-
imbursement on the Pharmaceutical Benefits
Scheme for treatment of this disease since 1
October 2015. Prior to this listing, the VEGF
inhibitor used to treat DME was off-label beva-
cizumab (AvastinTM; Genentech, Inc., San
Francisco, CA, USA). Bevacizumab and ranibi-
zumab are both recombinant antibodies to
VEGF-A (the latter is a small Fab antibody frag-
ment which binds to all isoforms of VEGF-A),
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while aflibercept is a soluble recombinant
human protein attached to the Fc portion of an
immunoglobulin G molecule; it has a higher
affinity for both VEGF-A and VEGF-B, as well as
to placental growth factors PIGF-1 and PIGF-2
that have also been identified as being impor-
tant in the pathogenesis of DME [14, 15].
In clinical trials and clinical practice treat
and extend (T&E) and pro re nata (PRN; ‘as
needed’) regimens of anti-VEGF treatment, in
response to signs of disease activity, have been
found to be beneficial in reducing the injection
burden on patients and improving the cost
effectiveness of treatment with little reduction
in clinical outcomes [16].
The aim of this study, initiated prior to
aflibercept being indicated for the treatment of
DME in Australia, was to assess the effectiveness
of a 2-year T&E regimen of aflibercept, in a
clinical setting, in patients with DME with no
history of intravitreal anti-VEGF therapy or in
those with relapsed DME with minimal expo-
sure (B 6 previous treatments) in the 12 months
prior to screening.
METHODS
Study Design
This study was an open-label, prospective,
investigator-led interventional study in a clinic
setting. Institutional ethics approval was
obtained from the Tasmanian Health and Medi-
cal Research Ethics Committee (THMREC) prior
to study commencement (Protocol Ref No:
H0014556) and registered with the Australian
New Zealand Clinical Trials Registry (ANZCTR;
ACTRN12618000428268). Informed consent
was obtained from all participants prior to
enrollment, in accordance with Springer’s ethi-
cal policies. The study adhered to the tenets of
the 1964 Declaration of Helsinki, as revised in
2013, and to the protocol approved by THMREC.
Participants
Patients aged[ 18 years with type 1 or type 2
diabetes mellitus who presented for routine
ophthalmologic examination and found to
have DME with central macular involvement
were invited to participate in the study. Eligible
participants had a study eye that met the fol-
lowing criteria: a best-corrected baseline visual
acuity (BCVA) of between 24 and 78 letters on
the Early Treatment Diabetic Retinopathy Study
(ETDRS) chart at 3 m; central retinal thickness
within 1 mm of the fovea (CFT) of C 300 lm
by spectral domain-optical coherence tomogra-
phy (OCT; Heidelberg Spectralis; Heidelberg
Engineering Inc., Heidelberg, Germany); no
anti-angiogenic drug treatment in the study eye
in the preceding 120 days and in the previous
90 days in the fellow eye; no more than two
macular laser photocoagulation treatments in
the previous 6 months; no pan-retinal photo-
coagulation (PRP) or macular laser photocoag-
ulation in the previous 90 days; no intra-ocular
or peri-ocular corticosteroid treatment in the
previous 120 days and no evidence of ocular or
peri-ocular infection, active proliferative dia-
betic retinopathy, visually significant cataract,
uncontrolled glaucoma, or other macular
pathology (e.g., laser burns or scars, wet age-
related macular degeneration, or macular holes)
that might influence the outcomes of the study.
Patients were also excluded if they had glyco-
sylated serum hemoglobin (HbA1c)[12% or
any other unstable systemic medical condition
at baseline. Diagnosis was confirmed by fluo-
rescein angiogram, and only one eye was
selected as the study eye. If the patient had two
eyes with DME the most recently diagnosed eye
was selected as the study eye.
Study Assessments
Assessments at each study visit included BCVA
intra-ocular pressure (Icare; Tiolat Oy, Helsinki,
Finland), OCT scans and slit lamp examination.
At baseline and study completion, participants
also underwent color fundus photography
(CentreVue Digital Retinography System; Cen-
tervue S.p.A, Padova, Italy) and fluorescein
angiography (Heidelberg Spectralis; Heidelberg
Engineering Inc.) if indicated. At each follow-up
visit, participants were asked about any adverse
events and any changes in their health or
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medications. All serious adverse events were
reported to the manufacturers and the local
ethics committee.
Treatment Protocol
All participants were given five 4-weekly load-
ing doses of 2 mg/0.05 mL aflibercept from sin-
gle-use vials provided by Bayer Australia Ltd.
(Pymble, NSW, Australia). The intravitreal
injections were performed according to the
regular procedure of each investigator using a
30-gauge needle inserted after local anesthesia
and using aseptic technique. Post-injection,
hand movement perception was confirmed, the
eye was irrigated with saline, and artificial tear
drops were administered if required.
After the first five monthly loading injec-
tions, treatment intervals were determined
according to a T&E regimen, based on the
presence of disease activity, i.e., a loss of C 5
BCVA letters at any time during the study
(considered by the treating physician to be
attributable to disease activity) or persistent
macular edema (macular thickness of C 300 lm
or increase in CFT of 50 lm). If none of these
criteria were met, the participant’s injection
interval was increased by 2 weeks until a maxi-
mum of 12-weekly dosing was attained. If either
criteria were met, the injection interval
decreased by 2 weeks (if[ 4 weeks), or returned
to 4 weeks (at the discretion of the investigator)
until disease activity was minimized. Partici-
pants who experienced significant and rapid
progression of disease or became unresponsive
to aflibercept had the option to withdraw and
have rescue therapy, such as, for example, laser
photocoagulation therapy or intravitreal
steroids.
Outcome Measures
The primary outcome measures were the mean
change in BCVA and the proportion of partici-
pants with a change in BCVA of C 5 and C 10
letters between baseline and 2 years of follow-
up. Secondary efficacy endpoints were the mean
changes in CFT and central macular volume
within 6 mm of the fovea (CSVol) between
baseline and 2 years and the frequency of
aflibercept injections over the course of the
study.
Statistical Analysis
Statistical analyses were performed in the R
statistical environment (R Development Core
Team, 2014; R Foundation for Statistical Com-
puting, Vienna, Austria). Continuous and cate-
gorical variables were summarized as means
with standard deviation (SD) and frequencies
(percentages), respectively, as appropriate.
Mean changes in continuous variables were
assessed using linear mixed models regression
to account for the correlation in observations
from the same individual over time. Predictors
included in the full model for each outcome
variable were visit, age, sex, intra-ocular pres-
sure, treatment number, lens status, previous
laser treatment (PRP), the number of PRP treat-
ments, and baseline HbA1c. Final models for
each outcome were generated using stepwise
regression to eliminate non-significant vari-
ables. A binomial variable was also used to
evaluate the effect of presenting with BCVA\
69 vs. C 69 ETDRS letters at baseline. For all
analyses p values of\ 0.05 were considered to
be statistically significant. The results of this
study are presented in accordance with inten-
tion-to-treat analysis, with the outcome mea-
sures of three patients who did not complete
the study carried forward.
RESULTS
Baseline Characteristics
Of the 36 patients consented and screened, 26
(61% male) were eligible to participate in the
study and completed the loading phase. Partic-
ipant characteristics are presented in Table 1. Of
the 26 eyes included in the study, nine of 14
right eyes and eight of 12 left eyes were phakic.
At baseline, the mean BCVA was ETDRS 69.7
(range 59–78) letters and the mean CFT and
CSVol were 416.6 (range 309–725) lm and 10.0
(range 7.4–13.5) mm3, respectively. Male
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participants had a slightly higher BCVA, with
correspondingly lower CFT and CSVol, than
female participants, but none of these differ-
ences were statistical significance.
Eighteen participants (12 male, 6 female)
had a BCVA of C 69 (mean 73.2, SD 3.4) letters,
and eight participants (4 male, 4 female) had a
BCVA of\ 69 (mean 61.9, SD 2.7) letters, but
there were no significant differences in mean
CFT or CSVol of eyes with BCVA of\69 letters
and BCVA C 69 letters: 394.4 (SD 81.4) vs.
426.4 lm (SD 134.4) and 9.72 (SD 1.4) vs.
10.3 mm3 (SD 1.72), respectively.
At baseline, 21 eyes (81.7%) had severe and
five eyes had moderate DME [17], and review of
fundal photographs indicated that 12 eyes had
mild, eight had moderate, and six had severe
non-proliferative diabetic retinopathy. Thirteen
eyes had previously been treated with PRP and
seven eyes previously treated with bevacizumab
had a mean of 3.1 (SD 2.7) injections in the year
prior to screening. Baseline HbA1c ranged from
6.2 to 11.1%, and although the majority of
participants (22/26) were insulin dependent
only three had type 1 diabetes.
Visual Acuity
Mean BCVA and a summary of the change in
BCVA over the course of the study are presented
in Table 2. After 2 years of aflibercept treatment,
the BCVA of 12 participants (46%) had
improved by C 5 letters and a further eight
participants had maintained their baseline
BCVA (Table 2). The mean change in BCVA at 6,
12, and 18 months and 2 years after adjustment
for significant covariates, namely, age, sex, and
baseline HbA1c, is presented for the overall
study population in Table 3 and illustrated
according to baseline BCVA (\69 letters or
Table 1 Participant characteristics at baseline
Participant characteristics All Males Females
Patients, n (right eyes) 26 (14) 16 (9) 10 (5)
Age, years 67.4 (10.6) 68.8 (9.9) 62.2 (11.70
Phakic:pseudophakic eyes, n 9:17 6:10 3:7
BCVA, EDTRS letters 69.7 (6.2) 70.9 (6.3) 67.8 (5.6)
CFT, lm 416.6 (121.3) 404.4 (93.5) 436.1 (157.1)
CSVol mm3 10.0 (1.6) 10.0 (1.5) 10.3 (1.5)
Diabetes mellitus type 1, n 3 2 1
Insulin treatment, n 22 13 9
Baseline HbA1c, % 8.16 (1.32) 7.8 (1.36) 8.64 (1.17)
De novo ME, n 15 11 4
Diabetic retinopathy history, years 4.1 (3.4) 3.8 (3.0) 4.7 (3.2)
Previous laser, n 13 9 4
Previous anti-VEGF, n 7 4 3
Values in table are presented as the mean with the standard deviation (SD) in parenthesis, unless indicated otherwise
BCVA Best-corrected visual acuity measured after refraction using Early Treatment Diabetic Retinopathy Study (ETDRS)
charts, CFT central retinal thickness within 1 mm of the fovea, CSVol central subfoveal volume within 6 mm of the fovea,
HbA1c glycosylated hemoglobin, ME macular edema, n number of participants (eyes) in that category, VEGF vascular
endothelial growth factor
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C 69 letters) in Fig. 1. The greatest improve-
ments in vision were observed within the first
few months of treatment. At 6 months, the
mean improvement in visual acuity was 3.7
letters. Thereafter, BCVA varied in a see-saw
pattern, being most evident in participants with
a baseline BCVA of\69 letters. Although the
initial gains in vision were maintained
throughout study duration, there was no addi-
tional significant improvement in BCVA
between 6 months and 2 years (Table 3) and no
statistically significant difference between the
Table 2 Participant vision and retinal morphology over the study period
BCVA and retinal morphology Time post commencement of aflibercept treatment
6 months 1 year 18 months 2 years
Mean number of BCVA letters 73.5 (9.4) 74.3 (9.4) 72.3 (12.0) 73.8 (10.7)
Change in number of BCVA (letters), n
Gain of C 15 letters 0 0 0 1
Gain of 10–14 letters 5 6 2 6
Gain of 5–9 letters, 5 9 11 7
Loss or gain of\ 5 letters 14 8 8 8
Loss of 5–9 letters 2 2 2 2
Loss of C 10 letters 0 1 3 2
Mean CFT, lm 298.6 (58.7) 295.4 (47.6) 286.7 (42.6) 290.1 (61.9)
Change in CFT, n
Reduced by C 50 lm 16 15 16 15
Reduced/increased by\ 50 lm 10 9 8 8
Increased by C 50 lm 0 1 2 1
Mean CSVol, mm3 8.7 (0.9) 8.5 (0.8) 8.5 (0.7) 8.5 (0.8)
Change in CSVol, n
Reduced by C 1.0 mm3 15 15 16 15
Reduced/increased by\ 1.0 mm3 11 11 8 9
Increased by C 1.0 mm3 0 0 1 2
Diabetic macular edema, n [17]
Severe 9 6 6 9
Moderate 11 7 4 1
Mild 4 7 8 5
None 2 6 8 11
Values in table are presented as the mean with the SD in parenthesis, unless indicated otherwise
n Number of participants (eyes) in that category
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mean vision gained in eyes with BCVA C 69
letters and those with BCVA\ 69 letters at
baseline (Fig. 1) or between naive participants
and those with previous bevacizumab exposure.
Anatomical Measures
Significant reductions in mean CFT were
observed after one aflibercept injection, and at
6 months the proportion of participants with
severe DME dropped to 34.6%; 57% of partic-
ipants had a decrease in CFT of C 50 lm
(Table 1), and the mean CFT had decreased
from 416.6 to 290.6 lm. The mean change in
CFT, after adjustment for covariates (age, sex,
and previous laser treatment), is presented in
Table 3 and illustrated, according to baseline
BCVA, in Fig. 2a. The mean reduction in CFT
after 2 years of intravitreal aflibercept treat-
ment was 127.2 (95% confidence interval
162.5, 91.5) lm, but although the mean CFT
continued to decrease over the course of the
study, the additional reduction of 10 lm after
6 months was not statistically significant
(Table 3).
At baseline the mean CFT of participants
with a BCVA of\ 69 letters was lower than that
of participants with a BCVA of [ 68 letters
(Fig. 2a), but the differences between the two
groups were not statistically significant at any
time point, and the median change in CFT over
the course of the study was similar in both
groups (- 92.5 lm and - 80 lm respectively).
Changes in CFT were accompanied by a signif-
icant reduction of 1.6 mm3 in CSVol, from
10.1 mm3 at baseline to 8.5 mm3 after 2 years
(Tables 2, 3; Fig. 2b). On average, participants
previously treated with PRP laser treatment or
bevacizumab had reductions in CFT of 35 lm
and 36 lm, respectively, greater than naive
patients (p\ 0.05).
Number and Frequency of Aflibercept
Injections
Twenty-five patients completed 1 year and 23
completed 2 years of follow-up. In the first year:
three participants had their follow-up/treat-
ment interval extended to 12 weeks, four were
extended to 10 weeks, six to 8 weeks and
6 weeks, while ten participants were maintained
on a 4-weekly treatment regimen. In the second
year, 18 of the remaining 25 participants (72%)
had treatment intervals extended to[ 8 weeks
16 at intervals of 12 weeks.
Of the 23 participants who completed the
study, the mean number of injections admin-
istered at the end of the first year was 11.2
(median 11; SD 1.56). In the second year this
was reduced to 6.9 (median 6; SD 3.2). There
were no significant differences between the
mean number of injections given to patients
with BCVA C 69 or\69 letters at baseline.
Fifteen participants (5 female, 10 male)
required bilateral anti-VEGF treatment over the
course of the study (2 bevacizumab, 2 ranibi-
zumab, and 11 aflibercept). Ten were diagnosed
with clinically significant macular edema in
their fellow eye at the same time as, or shortly
after, commencing the study, but there were no
statistically significant differences in any study
outcomes between those receiving unilateral or
bilateral anti-VEGF treatments.
Adverse Effects
Adverse events occurring over the course of the
study are listed in Table 4.
Participant Withdrawal
Two male participants failed to complete the
study due to unrelated serious adverse events
that resulted in death: One after only 7 months
treatment due to complications of a viral lung
infection; the second at 21 months when he
developed congestive cardiac failure associated
with a concomitant heart condition. In addi-
tion, a female resident of a nursing home
withdrew at 23 months due to logistical issues
(Table 4).
Other Adverse Events
The most commonly reported ophthalmic
adverse events were progression of bilateral
cataract, visual disturbance (spots/floaters),
subconjunctival hemorrhage, and sticky/gritty
eyes. Two participants developed vitreous
hemorrhage in the second year of the study. but
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there were no instances of endophthalmitis or
retinal detachment.
The most commonly reported non-ocular
adverse events were respiratory tract infections
and complications associated with concomitant
disease, most commonly diabetes (unsta-
ble blood sugars and complications associated
with diabetic renal disease) or cardiovascular
disease. Two patients had thromboembolic
events that led to hospitalization.
DISCUSSION
This study has demonstrated that significant
improvements in visual acuity and a reduction
in DME severity are possible using a T&E regi-
men of aflibercept in routine clinical practice
over a period of 2 years. Approximately 54% of
participants improved their visual acuity by C 1
line, and 69% had an improvement in the
severity of their DME.
The observed improvement in participant
visual acuity over 2 years (4 letters) was, how-
ever, lower than that observed in two pivotal
large randomized clinical trials (VISTA and
VIVID) [13] in which aflibercept was adminis-
tered every 4 or 8 weeks after five monthly
loading injections and the mean improvement
in vision was 10.7 and 12.5 letters, respectively.
Our results were similarly modest when com-
pared to the Diabetic Retinopathy Clinical
Research Network (DRCR.net) Protocol T study
[18, 19], which compared the efficacy of
aflibercept with ranibizumab and bevacizumab
treatment for DME when all were used accord-
ing to the same treatment regimen: six monthly
Fig. 1 Change in best-corrected visual acuity (BCVA)
Early Treatment Diabetic Retinopathy Scale (ETDRS)
letter score over the course of the study for all participants
and according to baseline BCVA. Change in BCVA was
adjusted for repeated measures, patient age, sex, baseline
glycosylated hemoglobin and baseline BCVA. Error bars
indicate the standard deviation (SD)
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loading injections followed by monthly follow-
up visits for review and intravitreal injection
and complete focal grid laser therapy as
required. After 2 years, the mean BCVA of par-
ticipants receiving aflibercept had improved by
12.8 letters compared to 10 letters and 12.3
letters for bevacizumab and ranibizumab,
respectively [19].
A possible explanation for the lower
improvement in mean BCVA observed in our
participants may be the observation made by
the DRCR investigators that the level of
improvement in vision in patients treated with
aflibercept over the course of 2 years was
dependent on the baseline visual acuity score
[19]. Although the baseline visual acuity inclu-
sion criteria for this study was in accordance
with those for the VIVID/VISTA [12] and
DRCR.net Protocol T [19] trials (between 24 and
78 EDTRS letters), none of our participants had
a baseline BCVA of\50 letters. Mean baseline
BCVA for the participants in our study was 70
letters overall (61 letters in those with BCVA\
69 letters) compared to 60 and 65 letters for the
VISTA/VIVID [12] and DRCR.net Protocol T [19]
trials, respectively. In addition, 50% of Protocol
T participants had a visual acuity of\ 69 letters
at baseline compared to only 30% of our par-
ticipants. Our study is therefore more prone to
the ceiling effects limiting the total number of
letters that may be gained by individual partic-
ipants with baseline BCVA of C 70 letters. The
higher baseline BCVA in our participants is a
likely consequence of our source population,
who were patients attending clinic for regular
ophthalmic review which facilitates earlier
detection of visual decline and recommence-
ment of treatment where appropriate. Patients
bFig. 2 a Mean change in central retinal thickness within
1 mm of the fovea (CFT) over the course of 2 years of
aflibercept treatment for all participants and according to
baseline BCVA. b Mean change in central subfoveal
volume within 6 mm of the fovea (CSVol) over the course
of 2 years of aflibercept treatment, for all participants and
according to baseline BCVA. CFT was measured by
spectral domain-optical coherence tomography (Heidel-
berg Spectralis; Heidelberg Engineering Inc., Heidelberg,
Germany). CFT and CSVol adjusted for repeated mea-
sures, patient age, sex, baseline glycosylated hemoglobin,
and previous laser therapy. Error bars indicate the SD
Table 4 Serious adverse events and non-serious adverse events observed/reported by more than one participant over the
course of the study
Ophthalmic events Total number Serious Non-ophthalmic events Total Serious
Cataract 6 Cold/flu symptoms 10 0
Visual disturbance (spots/floaters) 6 Hypo/hyperglycemia 4 2
Subcutaneous hemorrhage 7 Chest infection 4 2
Post-injection pain 2 Renal failure 2 1
Stinging eyes 2 Allergy NOS 2 1
Gastroenteritis 2 1
Vitreous hemorrhage 2 2 Cerebrovascular accident 1 1
Congestive cardiac failure 1 1
Myocardial infarction 1 1
Angina exacerbation 1 1
Hypocalcemia 1 1
Respiratory failure 1 1
NOS Not otherwise specified
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recruited into large industry-funded clinical
trials may be more likely to include those who
might not be able to afford regular visits to an
ophthalmology clinic and whose disease may
have gone unchecked until study recruitment.
In contrast to the BCVA, mean baseline CFT
and CSVol in this study were comparable to the
aflibercept arm of Protocol T (CFT 416 [SD
121] lm and CSVol 10.1 [SD 1.6] mm3 vs. CFT
412 [SD 130] lm and CSVol 8.9 [SD 1.9] mm3,
respectively) [19]. The change in CSVol was
similar in the two studies (- 1.58 [SD 1.72] mm3
vs. - 1.7 [SD 1.6 ] mm3, respectively), but the
mean improvement in CFT observed between
baseline and 2 years was 50 lm less in all but
two participants in our study, who were non-
compliant with their 4-weekly injection sched-
ule, with a reduced CFT.
At 2 years, previous exposure to PRP was
associated with a greater reduction in CFT.
However, although the current study protocol
included focal laser therapy as a potential rescue
measure, none of our participants with persis-
tent severe DME (34.6%) were administered this
treatment over the 2 years of the study as, with
the exception of two patients (with reductions
in BCVA of 9 and 11 letters), their vision was
either maintained or improved. Over the 2 years
of the Protocol T study, 31% of patients in the
aflibercept arm had at least one session of focal
grid laser therapy for persistent DME [19]. It is
possible that if our participants had received
treatment our outcomes may have been more
comparable, although a post hoc analysis of
Protocol T data suggested that any additional
benefit of focal laser therapy was only apparent
in participants with poor vision who were in the
bevacizumab arm of the trial [20].
In a post hoc analysis, participants with anti-
VEGF exposure prior to commencing the study
had a greater reduction in CRT compared to
naive participants. This is in contrast to the
results of the VISTA [21] and Protocol T [19],
where visual and anatomical outcomes of
patients in the aflibercept arms of the study
were independent of previous anti-VEGF expo-
sure. Further investigation of this and other
contributory factors that may be associated with
better outcomes in previously treated patients
was outside the scope of this study.
This study was initiated prior to the publi-
cation of the DRCR.net Protocol T trial that
demonstrated the effectiveness of a PRN treat-
ment schedule and before aflibercept was rou-
tinely available for the treatment of DME in
Australia. The T&E regimen is regarded as a
proactive, cautious approach to treatment
which minimizes disease recurrence and redu-
ces the number of patient visits to clinic [16]. In
addition to freeing up clinic time for others, this
regimen can make clinic visits less stressful for
patients as they can anticipate the treatment
and will be able to plan their visit (e.g., trans-
port requirements) accordingly. In the current
study, the median number of aflibercept treat-
ments (11 (interquartile range [IQR] 10–12) in
the first year and six (IQR 5–8.5) in the second
year) was comparable to that observed in the
Protocol T (9 (IQR 8–11) and 5 (IQR 2–7) in the
first and second years, respectively). The
downside of T&E regimens, however, is that
patients are treated at pre-defined intervals and
when treatment might be deemed unnecessary
in a PRN regimen. Of the 12 participants who
had their treatment intervals extended to
12 weeks, 11 continued to receive aflibercept
treatment at 12-weekly intervals with no evi-
dence of DME on the OCT scans. Such unnec-
essary treatments expose patients to increased
risk of adverse events associated with intravit-
real injection and would also make the cost of
treatment more expensive than it need be.
Therefore, physicians need to consider the risks
and benefits of any treatment regimen to indi-
vidual patients.
The weaknesses of this study include the lack
of any comparator group and its sample size. As
observed in other anti-VEGF T&E studies, the
changes in visual acuity, CFT, and CSVol over
the 2 years (Figs. 1, 2) fluctuated over time as
participant treatment intervals were extended.
Smaller sample size results in greater fluctua-
tions as individual participant results have more
weight over the sample. This was particularly
evident among participants with a BCVA of\
69 letters, when our data was stratified
according to baseline BCVA, where delays to
treatment, caused by one patient’s non-com-
pliance, had a negative effect on improvements
previously observed.
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This is the first 2-year prospective study of
aflibercept for DME conducted in a routine
clinical situation in patients with no or minimal
recent exposure to anti-VEGF treatment. The
few clinic-based prospective T&E studies con-
ducted to date have investigated the efficacy of
bevacizumab [22] or ranibizumab [23–25], but
most prospective studies have concentrated on
the outcomes of aflibercept treatment in
patients non-responsive to other anti-VEGF
treatments [26–29] or using loading followed by
an 8-weekly regimen [30], with results similar to
that observed in the VIVA/VISTA.
CONCLUSION
The results of this study indicate that a T&E
regimen of aflibercept is effective and a practical
alternative to a PRN treatment schedule for the
majority of patients presenting with DME.
Extension periods beyond 12 weeks should be
employed to reduce patient overtreatment, but
the latter is more likely in the third year of
treatment and beyond.
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